Study Details

Back to Search Results

An Open-label Phase I Study of orally available novel small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 inhibitor, ASP5878 at Single and Multiple Doses in Patients with Solid Tumors

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02038673

Astellas Study ID

The unique identification code given by the study sponsor.

5878-CL-0101

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Advanced/Metastatic Cancer

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

20 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Nov 2013 - Jul 2017

Masking

None (Open Label)

Enrollment number

86

An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients with Solid Tumors

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for An Open-label Phase I Study of orally available novel small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 inhibitor, ASP5878 at Single and Multiple Doses in Patients with Solid Tumors? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site JP117

Niigata, Japan

Site JP118

Osaka, Japan

Site JP112

Nagoya, Japan

Site KR202

Gyeonggi-do, Republic of Korea

Site JP106

Osaka, Japan

Site JP107

Tokyo, Japan

Site US405

Cleveland, United States, 44195

Site JP121

Okayama, Japan

Site JP124

Shizuoka, Japan

Site JP113

Hyogo, Japan

Site KR204

Seoul, Republic of Korea

Site TW302

Tainan, Taiwan, Province of China

Site US402

Orange, United States, 92868

Site JP123

Tokyo, Japan

Site TW301

Taipei, Taiwan, Province of China

Site JP103

Ibaraki, Japan

Site JP120

Fukuoka, Japan

Site JP111

Ishikawa, Japan

Site US406

Spartanburg, United States, 29303

Site JP104

Osaka, Japan

Site US410

Fairfax, United States, 22031

Site TW303

Taipei, Taiwan, Province of China

Site KR201

Seoul, Republic of Korea

Site KR203

Seoul, Republic of Korea

Site JP119

Kanagawa, Japan

Site US401

New York, United States, 10032

Site US412

Detroit, United States, 48201

Site JP109

Miyagi, Japan

Site JP102

Tokyo, Japan

Site JP101

Kyoto, Japan

Site US404

Cleveland, United States, 44106

Site JP122

Chiba, Japan

Site JP110

Miyagi, Japan

Site JP108

Fukuoka, Japan

Site JP116

Hokkaido, Japan

Site JP114

Tokyo, Japan

Site US403

Seattle, United States, 98109

Site JP115

Fukuoka, Japan

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo